Nexavar
Links shared publicly online about this topic
Nexavar May Treat Advanced Breast Cancer
webmd.com — “Adding the cancer drug Nexavar to standard chemotherapy significantly extends the time until advanced breast cancer progresses, researchers report.” View full resource at webmd.com
Most Recently Shared on September 24, 2009 at 7:07 pm By:
Nexavar May Treat Advanced Breast Cancer: Adding the cancer drug Nexavar to standard chemotherapy significantly.. http://bit.ly/t9O34
Bayer's Nexavar shows promise in lung cancer study | Reuters
reuters.com — “FRANKFURT, May 15 (Reuters) - Bayer's cancer drug hopeful Nexavar showed promise as a lung-cancer treatment in a Phase II study, the ASCO association of U.S. oncologists said on its Website” View full resource at reuters.com
Most Recently Shared on May 16, 2009 at 6:11 am By:
H. Jack West, MD Internist, Health Executive, Oncologist, Physician, and Doctor
be wary of pharma hyping mild results to (over)sell hope: http://tinyurl.com/nexphII not every study that is a C- merits a press release.
Phase 3 study of Nexavar for the treatment of breast cancer - ONA
oncologynurseadvisor.com — “Bayer and Onyx began enrollment of their Phase 3 study of Nexavar (sorafenib; Bayer and Onyx) in combination with capecitabine for the treatment of patients with advanced breast cancer.” View full resource at oncologynurseadvisor.com
Most Recently Shared on February 24, 2011 at 4:52 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 3 study of Nexavar for the treatment of breast cancer http://goo.gl/fb/sGy7V
Onyx, Bayer say Nexavar fails in lung cancer study - Topix
topix.com — “Onyx, Bayer say Nexavar fails in lung cancer study - Topix” View full resource at topix.com
Most Recently Shared on June 14, 2010 at 8:39 pm By:
Onyx, Bayer say Nexavar fails in lung cancer study: Bayer HealthCare and Onyx Pharmaceuticals Inc. said Monday the... http://bit.ly/cbggPW
Phase 3 study of Nexavar for the treatment of breast cancer - MPR
empr.com — “Bayer and Onyx began enrollment of their Phase 3 study of Nexavar (sorafenib; Bayer and Onyx) in combination with capecitabine for the treatment of patients with advanced breast cancer.” View full resource at empr.com
Most Recently Shared on February 24, 2011 at 4:57 pm By:
MPR News: Phase 3 study of Nexavar for the treatment of breast cancer: Bayer and Onyx began enrollment of their ... http://bit.ly/e64wS6
Nexavar disappoints in another lung-cancer trial - FiercePharma
fiercepharma.com — “Bayer has met with another setback in its quest to extend Nexavar use to lung-cancer patients. The drug failed to extend the lives of patients with non-small cell lung cancer when used as a... Read more...” View full resource at fiercepharma.com
Most Recently Shared on June 14, 2010 at 2:06 pm By:
Nexavar disappoints in another lung-cancer trial. http://bit.ly/b6lUpU
Phase 3 study of Nexavar and Tarceva for primary liver cancer - MPR
empr.com — “Bayer HealthCare, Onyx Pharmaceuticals, OSI Pharmaceuticals and Roche announced the initiation of a Phase 3 trial examining Nexavar (sorafenib tablet, from Bayer and Onyx) in combination with Tarceva (erlotinib tablet, from Genentech) for the treatment of patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.” View full resource at empr.com
Most Recently Shared on May 28, 2009 at 5:12 pm By:
MPR News: Phase 3 study of Nexavar and Tarceva for primary liver cancer: Bayer HealthCare, Onyx Pharmac.. http://tinyurl.com/mvbu2k
NICE nixes Nexavar for liver cancer - FiercePharma
fiercepharma.com — “The U.K.'s cost watchdogs strike again. The National Institute for Health and Clinical Excellence gave Bayer's cancer drug Nexavar the heave-ho, saying it shouldn't be given to National Health... Read more...” View full resource at fiercepharma.com
Most Recently Shared on May 7, 2009 at 5:07 pm By:
Jonathan Richman Health Executive
Nexavar nixed by NICE. Aren't you glad you live in the US where the government doesn't block access to certain drugs? http://bit.ly/zl9Dg
Bayer's NEXAVAR approved in over 70 countries for the treatment of liver cancer
news-medical.net — “Bayer Inc. announced today that its international trial known as SHARP (Sorafenib HCC Assessment Randomized Protocol), led by Study Manager and Bayer Canada employee Tom Giannaris, has been selected as the winner in the 'Best International Trial' category for the Global Clinical Practice Journal Awards.” View full resource at news-medical.net
Most Recently Shared on November 17, 2009 at 11:12 pm By:
News-Medical.Net Health News and Oncology
Oncology News: Bayer's NEXAVAR approved in over 70 countries for the treatment of liver cancer: B.. http://bit.ly/UIkry
Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer... | Reuters
reuters.com — “Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress WAYNE, N.J. and” View full resource at reuters.com
Most Recently Shared on September 15, 2009 at 5:05 pm By:
Wow--30 studies on Nexavar being presented at ECCO/ESMO next week http://tinyurl.com/mtupmf
Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting - Drugs.com MedNews
drugs.com — “Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting WAYNE, N.J. and SOUTH SAN FRANCISCO, May 18, 2011 PRNewswire Bayer HealthCa” View full resource at drugs.com
Most Recently Shared on May 19, 2011 at 3:06 pm By:
Drugs and Devices OW OW Health
Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting: Nexavar Data to Be P... http://bit.ly/jtVCLD #drug
Nexavar Data To Be Presented At 46th American Society Of Clinical Oncology Annual Meeting
medicalnewstoday.com — “Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that more than 70 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented a” View full resource at medicalnewstoday.com
Most Recently Shared on May 26, 2010 at 7:13 pm By:
MNT Med Conferences Health News
Nexavar Data To Be Presented At 46th American Society Of Clinical Oncology Annual Meeting http://mnt.to/3D6k #medicalconferences
BAYNEWS - The Bayer Press Server - Phase III Trial Started to Evaluate Combination Therapy of Nexavar and Tarceva in Patients with Liver Cancer
press.bayer.com — “BAYNEWS - The Bayer Press Server - Phase III Trial Started to Evaluate Combination Therapy of Nexavar and Tarceva in Patients with Liver Cancer” View full resource at press.bayer.com
Most Recently Shared on May 28, 2009 at 1:42 pm By:
eyeonfda Pharma and Health Lawyer
Phase III Trial Started to Evaluate Combination Therapy of Nexavar® and Tarceva® in Patients with Liver Cancer - http://bit.ly/14vhJ9
Phase 3 study of Nexavar for the treatment of non-responsive thyroid cancer - MPR
empr.com — “Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals announced the initiation of patient enrollment in their DECISION study, a Phase 3 trial to evaluate Nexavar (sorafenib tablets) for the treatment of patients with iodine-refractory, locally advanced or metastatic differentiated thyroid cancer.” View full resource at empr.com
Most Recently Shared on October 23, 2009 at 3:16 pm By:
MPR News: Phase 3 study of Nexavar for the treatment of non-responsive thyroid cancer: Bayer HealthCar.. http://bit.ly/4zca6z
Pfizer's axitinib impresses in head-to-head trial with Nexavar | InPharm
inpharm.com — “InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, jobs, events, and service company listings.” View full resource at inpharm.com
Most Recently Shared on November 22, 2010 at 9:54 am By:
Pharmafocus Health News and Pharma
Pfizer's axitinib impresses in head-to-head trial with Nexavar http://ht.ly/3dtjO
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
WebMD_News
The leading source for trustworthy and timely health news and information.
-
H. Jack West, MD
Seattle-based medical oncologist, Founder & President of cancer education non-profit Global Resource for Advancing Cancer Education (GRACE)
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
Advertisement
